Elizabeth Yeu Lin - 31 Dec 2021 Form 3 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
31 Dec 2021
Net transactions value
$0
Form type
3
Filing time
04 Jan 2022, 20:09:23 UTC
Previous filing
25 Jun 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TARS Employee Stock Option (right to buy) 31 Dec 2021 Common Stock 2,019 $2.01 Direct F1
holding TARS Employee Stock Option (right to buy) 31 Dec 2021 Common Stock 33,372 $10.99 Direct F2
holding TARS Employee Stock Option (right to buy) 31 Dec 2021 Common Stock 4,543 $10.99 Direct F3
holding TARS Employee Stock Option (right to buy) 31 Dec 2021 Common Stock 5,200 $34.72 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). 504 of the option shares vest and become exercisable on April 16, 2021. The remainder of the option shares vest and become exercisable in 36 equal monthly installments beginning May 16, 2021.
F2 Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on September 1, 2020.
F3 Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.
F4 Option granted under the Plan. The option shares vest and become exercisable on March 2, 2022.

Remarks:

Exhibit 24 - Power of Attorney